Commitment to Care
Trusted Since 19851*

*FDA approved in 1985, the first GnRHa for the treatment of advanced prostate cancer patients.1
Lucas, age 64
Semi-retired financial analyst, passionate cook,
husband and father

Not an actual patient.

LUPRON DEPOT, an androgen deprivation therapy (ADT), has been a pioneer in the treatment of advanced prostate cancer.1

A Wealth of Experience

Our commitment to your patients will be as strong tomorrow as it is today.

The number one prescribed icon

#1 Prescribed

America’s most-prescribed
GnRHa2†

Calendar icon

35+ Years

The most clinical experience of
any GnRHa on the market1‡

Group of men icon

Millions of injections
administered3§

Based on IQVIA NSP data.
FDA approved in 1985, the first GnRHa for the treatment of advanced prostate cancer patients.1
§Based on MEU sales data as of 2017-2022.
GnRHa=gonadotropin-releasing hormone agonist.
Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge
Based on IQVIA NSP data.
FDA approved in 1985, the first GnRHa for the treatment of advanced prostate cancer patients.1
§Based on MEU sales data as of 2017-2022.
GnRHa=gonadotropin-releasing hormone agonist.

A Number of Firsts

From day 1, LUPRON DEPOT has been committed to the treatment of advanced prostate cancer.

1985

LUPRON DEPOT became the first approved GnRHa for the palliative treatment of advanced prostate cancer1

1989

First and only GnRHa prefilled dual-chamber syringe. No external mixing required. Flexible dosing options4-11

2007

Launched LuproLink Inventory Management System

2016

Dosage and administration section of the label updated to include continued treatment in patients who develop metastatic CRPC4,11

2019

Dosage and administration section of the label updated to include continued treatment in patients who develop nonmetastatic or metastatic CRPC4,11

2022

LUPRON DEPOT is indicated for treatment of advanced prostate cancer4

CRPC=castration-resistant prostate cancer.

Coverage

We are committed to making LUPRON DEPOT accessible for patients.

>99%
of lives

LUPRON DEPOT is covered for >99% of lives with national commercial insurance, Medicaid, and Medicare Part B combined12*†

~100%
covered

LUPRON DEPOT is covered for ~100% of Medicare Part B lives12*†

Overview of Medicare Part B and D

Medicare
Part B

Part B is a medical benefit that covers services such as in-office administration for medications like LUPRON DEPOT 

Part B may offer lower out-of-pocket costs for patients compared with Part D or commercial insurance pharmacy benefits

Medicare
Part D

Part D is a prescription drug benefit that covers medications dispensed through a pharmacy

Part D may have higher out-of-pocket costs than Part B

 

Source: Managed Markets Insight and Technology, LLC, a trademark of MMIT, as of November 2024. This analysis reflects medical insurance coverage only.
 

*

For those national commercial, Medicaid, and Medicare plans that report coverage data; excludes plans and payors with unknown coverage. 
 

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

RFID=radio-frequency identification.
#CRPC=castration-resistant prostate cancer.